Purdue licenses oxycodone to Covidien; Judge cuts Boston Sci patent payment;

> Settling a long-running patent dispute, Purdue Pharma has granted Covidien subsidiary Mallinckrodt a license to sell limited quantities of generic oxycodone through 2009. Purdue release

> Boston Scientific said a federal judge found two patents held by rival Medtronic to be unenforceable and slashed the damages Boston Scientific must pay in a patent-infringement case over the company's balloon catheters and stents. Report

> Novacea has inked a deal to merge with Transcept Pharmaceuticals via an all-stock transaction that will leave former Transcept shareholders with 60 percent of the combined company. Novacea release

> Fulcrum Pharma Chairman Sir Charles George will retire at the company's annual meeting in December, and Grahame Cook has joined the board as a non-executive director and chairman designate. Report

> Akorn-Strides got the FDA nod for its dexamethasone sodium phosphate injection, which treats such conditions as endocrine disorders, arthritis, blood disorders and dermatologic diseases, among others. Report

> Sanofi-Aventis has completed the purchase of Symbion Consumer, an Australian company that manufactures, markets and distributes nutraceuticals and OTC brands in Australia and New Zealand. Report

> Economic conditions are catching up with biotech investing. Report

> ThromboGenics' current COO Patrik De Haes has been appointed to succeed Professor Désiré Collen as the company's new CEO. Report

> Affymax and partner Takeda have announced that they will suspend development of the drug Hematide for chemotherapy-induced anemia due to the "uncertain regulatory landscapes for erythropoiesis-stimulating agents (ESAs) in oncology indications." Report

> After a rough year, Pharmos Corporation announced in October of 2007 that it would be laying off half of the staff at its Israeli subsidiary. Report

> Researchers are hailing new work decoding a key enzyme as a breakthrough that could lead to an entirely new class of anti-cancer therapies. Report

And Finally... Researchers at the prestigious Karolinska Institute in Sweden have found a genetic variant that could explain why some men are dysfunctional when it comes to their relationships. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.